The FDA’s new Breakthrough status for new drug applications

May 24, 2013- Interviewed by Steven E. Greer, MD

Janet Woodcock, MD, the FDA’s Director of CDER (all new drugs) discusses the new regulatory pathway called “Breakthrough status”.

This entry was posted in - Pharma, FDA. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *